Skip to main content
TScan Therapeutics, Inc. logo

TScan Therapeutics, Inc. — Investor Relations & Filings

Ticker · TCRX ISIN · US89854M1018 US Professional, scientific and technical activities
Filings indexed 310 across all filing types
Latest filing 2022-02-04 Major Shareholding Noti…
Country US United States of America
Listing US TCRX

About TScan Therapeutics, Inc.

https://www.tscan.com

TScan Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of cancer. The company's approach is centered on discovering highly effective, naturally occurring TCRs and using them to genetically reprogram T cells. This strategy aims to harness the power of the human immune system to deliver safe and effective immunotherapies to patients.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2022
Major Shareholding Notification
2022-02-04 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated January 24, 2022. It announces FDA clearance of an IND application and a hold on another IND application, and includes a press release as an exhibit. The content is an event announcement rather than a full financial report or detailed filing. The document length is 3391 characters, which is relatively short and mainly contains an announcement and a press release. There are no financial statements or detailed financial data. Therefore, this is a Regulatory Filing (RNS) as it is a general regulatory announcement that does not fit into other specific categories.
2022-01-24 English
FORM 4 SUBMISSION
Director's Dealing
2022-01-20 English
FORM 4 SUBMISSION
Director's Dealing
2022-01-20 English
FORM 4 SUBMISSION
Director's Dealing
2022-01-20 English
FORM 4 SUBMISSION
Director's Dealing
2022-01-20 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.